Treating XDR-TB is complex and requires a combination of second-line anti-TB drugs for an extended period, typically ranging from 18 to 24 months or more. The treatment regimen must be carefully designed based on the individual’s drug susceptibility profile and may include newer drugs like bedaquiline and delamanid. Despite this, treatment outcomes are often less favorable compared to drug-susceptible TB.
